Particle.news
Download on the App Store
10 ARTICLES
·
last mo.

Argentina Secures US$8 Billion Clinical Research Pledge From Multinational Drugmakers

The pledge could expand clinical trials, create skilled jobs, boost export services contingent on patent-law reform plus regulatory approval.

Image
Maurice Ostro, conocido por su colección de gemas, explora la posibilidad de establecer infraestructura digital en Argentina, alineándose con las políticas libertarias.
Image
De acuerdo con los datos difundidos por CAEMe, de cada diez dólares que ingresan al país para financiar actividades empresariales de investigación y desarrollo, 9,5 dólares corresponden a investigación clínica.

Overview

  • CAEMe, the chamber that groups multinational innovators, announced a coordinated plan to mobilize US$8 billion for clinical research in Argentina over six years during a May 29 meeting at the Casa Rosada with President Javier Milei and Health Minister Mario Lugones.
  • The agreement links the investment drive to the government’s incentive framework, including the RIGI/Súper RIGI regime, and aims to strengthen research sites, hospital partnerships and workforce training for larger, internationally run trials.
  • CAEMe said clinical research already accounts for roughly half of private-sector R&D in Argentina with about 50,000 patients in 1,000 active trials and that its members provide the vast bulk of industry-sponsored R&D dollars.
  • The rollout faces a political hurdle because the investments are tied to possible patent-law changes and Argentina’s accession to international patent mechanisms, a reform that has majority committee backing but no scheduled final vote and that local generic producers oppose.
  • If parliamentary approval and regulatory details follow, the deal could bring export revenue and new skilled jobs to Argentina while raising questions about effects on domestic generics, trial site selection and the timing and geography of actual capital deployment.